Complement factor H or a related protein is a marker for transitional cell cancer of the bladder

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2511-2520

  Kinders, Robert ^a   Jones, Tobin ^a   Root, Richard ^a   Bruce, Connie ^a   Murchison, Heather ^a   Corey, Michael ^b   Williams, Lawrence ^a   Enfield, David ^a   Hass, G Michael ^a  

^a Bion Diagnostic Sciences   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; TUMOR MARKER;

ANIMAL MODEL; ARTICLE; BINDING SITE; BLADDER CARCINOMA; CANCER DIAGNOSIS; COMPLEMENT FIXATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOAFFINITY CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, TRANSITIONAL CELL; CHROMATOGRAPHY, AFFINITY; COMPLEMENT FACTOR H; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0031784226     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Osten, R. T. (ed.), Cancer Manual, 9th ed. Framingham, MA: American Cancer Society, 1996.
2. American Cancer Society. Cancer Facts and Figures, 1996. Framingham, MA: American Cancer Society, 1996.
3. Sarosdy, M. F., DeVere White, R. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G., and Blumenstein, B. A. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379-384, 1995.
4. Sarosdy, M. F., Hudson, M. A., Ellis, W. J., Soloway, M. S., deVere White, R. W., Sheinfeld, J., Jarowenko, M. V., Schellhammer, P. F., Schervish, E. W., Patel, J. V., Chodak, G. W., Lamm, D. L., Johnson, R. D., Henderson, M., Adams, G., Blumenstein, B. A., Thoelke, K. D., Pfalzgraff, R. D., Murchison, H. A., and Brunelle, S. L. Improved detection of recurrent bladder cancer using the Bard BTAstat test. Urology, 50: 349-353, 1997.
5. Ellis, W. J., Blumenstein, B. A., Ishak, L. M., and Enfield, D. L. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology, 50: 882-887, 1997.
6. Enfield, D. M., and Ishak, L. M. Hematuria and complement factor H-related protein levels in urine appear to be independent. J. Urol., 159 (Suppl. 5): 243, 1998.
7. Vik, D. P., Munoz-Canoves, P., Chaplin, D. D, and Tack, B. F. Factor H. Curr. Top. Immunol., 153: 147-162, 1989.
8. Sim, R. B., Day, A. J., Moffatt, B. E., and Fontaine, M. Complement factor I and cofactors in control of complement system convertase enzymes. Methods Enzymol., 223: 13-35, 1993.
9. Sharma, A. K., and Pangburn, M. K. Identification of three physically and functionally distinct binding sites of C3b in human complement factor H by deletion mutagenesis. Proc. Natl. Acad. Sci. USA, 93: 10996-11001, 1996.
10. Fishelson, Z. Complement C3: a molecular mosaic of binding sites. Mol. Immunol., 28: 545-552, 1991.
11. Holers, V. M., Kinoshita, T., and Molina, H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol. Today, 13: 231-236, 1992.
12. Sahu, A., and Pangburn, M. K. Identification of multiple sites of interaction between heparin and the complement system. Mol. Immunol., 30: 679-684, 1993.
13. Meri, S., and Pangburn, M. K. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. USA, 87: 3982-3986, 1990.
14. Meri, S., and Pangburn, M. K. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem. Biophys. Res. Commun., 198: 52-59, 1994.
15. Ollert, M. W., David, K., Bredehorst, R., and Vogel, C-W. Classical complement pathway activation on nucleated cells. Role of factor H in control of deposited C3b. J. Immunol., 155: 4955-4972, 1995.
16. De St. Groth, S. F., and Scheidegger, D. Production of monoclonal antibodies: strategy and tactics. M. Immunol. Methods, 35: 1-21, 1980.
17. Alsenz, J., Lambris, J. D., Schulz, T. F., and Dierich, M. P. Localization of the complement-component-C3b binding site and the cofactor activity for factor I in the 38 kDa tryptic fragment of factor H. Biochem. J., 224: 389-398, 1984.
18. Sim, R. B., Malhotra, V., Ripoche, J., Day, A. J., Micklem, K. J., and Sim, E. Complement receptors and related control proteins. Biochem. Soc. Trans., 51: 83-96, 1986.
19. Sambrook, J., Fritsch, E. F., and Maniatis, J. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
20. Corey, E., Arfman, E. W., Liu, A. Y., and Vessella, R. L. Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. Clin. Chem., 43: 443-452, 1997.
21. Becherer, J. D., Alsenz, J., Esparza, I., Hack, C. E., and Lambris, J. D. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry. 31: 1787-1794, 1992.
22. Estaller, C., Schwaeble, W., Dierich, M., and Weiss, E. H. Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts. Eur. J. Immunol., 21: 799-802, 1991.
23. Skerka, C., Timman, C., Horstmann, R. D., and Zipfel, P. F. Two additional human serum proteins structurally related to complement factor H. J. Immunol., 148: 3313-3318, 1992.
24. Zipfel, P. F., and Skerka, C. Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunol. Today, 15: 121-126, 1994.
25. Messing, E. M., Young, T. B., Hunt, V. B., Newton, M. A., Bram, L. L., Vaillancourt, A., Hisgen, W. J., Greenberg, E. B., Kuglitsch, M. E., and Wegenke, J. D. Hematuria home screening: repeat testing results. J. Urol., 154: 57-61, 1995.
26. Lappin, D. F., and Whaley, K. Interferon-induced transcriptional and post-transcriptional modulation of factor H and C4 binding protein synthesis in human monocytes. Biochem. J., 271: 762-777, 1990.
27. Van Den Dobbelsteen, M. E. A., Verhasselt, V., Kaashoek, J. G. J., Timmerman, J. J., Schroeijers, W. E. M., Verweij, C. L., Van Der Woude, F. J., Van Es, L. A., and Daha, M. R. Regulation of C3 and factor H synthesis of human glomerular mesangial cells by IL-1 and interferon. Clin. Exp. Immunol., 95: 173-180, 1994.
28. Guyton, A. C. Textbook of Medical Physiology, 7th ed., p. 398. Philadelphia: W. B. Saunders Co., 1986.
29. Gasque, P., Julen, N., Ischenko, A. M., Picot, C., Mauger, C., Chauzy, C., Ripoche, J., and Fontaine, M. Expression of complement components of the alternative pathway by glioma cells. J. Immunol., 149: 1381-1387, 1992.
30. Jarvis, G. A., Li, J., Hakulinen, J., Brady, K. A., Nordling, S., Dahiya, R., and Meri, S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int. J. Cancer, 71: 1049-1055, 1997.
31. Simpson, K. L., Jones, A., Norman, S., and Holmes, C. H. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal uterine cervix and in premalignant and cervical disease. Am. J. Pathol., 151: 1455-1467, 1997.
32. Niehans, G. A., Cherwitz, D. L., Staley, N. A., Knapp, D. J., and Dalmasso, A. P. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol., 149: 129-142, 1996.
33. Bjorge, L., Hakulinen, J., Wahlstrom, T., Matre, R., and Meri, S. Complement-regulatory proteins in ovarian malignancies. Int. J. Cancer, 70: 14-25, 1997.